About: Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Two-Year Follow-up of a Prospective Randomized Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Two-Year Follow-up of a Prospective Randomized Trial Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Randomized controlled trials studying the efficacy and safety of matrix-applied characterized autologous cultured chondrocytes (MACI) versus microfracture (MFX) for treating cartilage defects are limited. Purpose: To compare the clinical efficacy and safety of MACI versus MFX in the treatment of patients with symptomatic cartilage defects of the knee. Study Design: Randomized controlled clinical trial; Level of evidence, 1. Methods: Patients enrolled in the SUMMIT (Demonstrate the Superiority of MACI implant to Microfracture Treatment) trial had >= 1 symptomatic focal cartilage defect (Outerbridge grade III or IV; >= 3 cm(2)) of the femoral condyles or trochlea, with a baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) pain value <55. The co-primary efficacy endpoint was the change in the KOOS pain and function subscores from baseline to 2 years. Background: Randomized controlled trials studying the efficacy and safety of matrix-applied characterized autologous cultured chondrocytes (MACI) versus microfracture (MFX) for treating cartilage defects are limited. Purpose: To compare the clinical efficacy and safety of MACI versus MFX in the treatment of patients with symptomatic cartilage defects of the knee. Study Design: Randomized controlled clinical trial; Level of evidence, 1. Methods: Patients enrolled in the SUMMIT (Demonstrate the Superiority of MACI implant to Microfracture Treatment) trial had >= 1 symptomatic focal cartilage defect (Outerbridge grade III or IV; >= 3 cm(2)) of the femoral condyles or trochlea, with a baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) pain value <55. The co-primary efficacy endpoint was the change in the KOOS pain and function subscores from baseline to 2 years. (en)
Title	Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Two-Year Follow-up of a Prospective Randomized Trial Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Two-Year Follow-up of a Prospective Randomized Trial (en)
skos:prefLabel	Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Two-Year Follow-up of a Prospective Randomized Trial Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture Two-Year Follow-up of a Prospective Randomized Trial (en)
skos:notation	RIV/00216224:14110/14:00077193!RIV15-MSM-14110___
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	6
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Paša, Libor
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	27685
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/14:00077193
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	cartilage repair; clinical outcomes; knee; matrix-applied characterized autologous cultured chondrocytes (MACI) implant; microfracture (en)
http://linked.open.../riv/klicoveSlovo	knee microfracture cartilage repair clinical outcomes matrix-applied characterized autologous cultured chondrocytes (MACI) implant
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[04B1E872865B]
http://linked.open...i/riv/nazevZdroje	The American Journal of Sports Medicine
http://linked.open...in/vavai/riv/obor	FI
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	17 (xsd:int)
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	42
http://linked.open...iv/tvurceVysledku	Paša, Libor Bertrand-Marchand, Marion Bezuidenhoudt, Mauritz Brittberg, Mats Caron, Jacob Drogset, Jon Olav Emans, Pieter Kili, Sven Levine, David Podskubka, Ales Price, Andrew Sanson, Bernd-Jan Saris, Daniel Slynarski, Konrad Trc, Tomas Tsuchida, Anika Widuchowski, Wojciech
http://linked.open...ain/vavai/riv/wos	000340721400023
issn	0363-5465
number of pages	11 (xsd:int)
http://bibframe.org/vocab/doi	10.1177/0363546514528093
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 84 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software